Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

NHS Trust Focuses On Staff Health
Hydration expert, Water Wellpoint is playing a key role in helping public sector employers look after the health and wellbeing of their staff. The company has recently been working with East London NHS Foundation Trust to run a series of wellbeing days, giving employees the ability to check key aspects of their health in a total voluntary format.
generic viagra online
Potential Medical Applications For Interactive Data Eyeglasses
For car designers, secret agents in the movies and jet fighter pilots, data eyeglasses - also called head-mounted displays, or HMDs for short - are everyday objects. They transport the wearer into virtual worlds or provide the user with data from the real environment. At present these devices can only display information. "We want to make the eyeglasses bidirectional and interactive so that new areas of application can be opened up," says Dr. Michael Scholles, business unit manager at the Fraunhofer Institute for Photonic Microsystems IPMS in Dresden. A group of scientists at IPMS is working on a device which incorporates eye tracking - users can influence the content presented by moving their eyes or fixing on certain points in the image. Without having to use any other devices to enter instructions, the wearer can display new content, scroll through the menu or shift picture elements. Scholles believes that the bidirectional data eyeglasses will yield advantages wherever people need to consult additional information but do not have their hands free to operate a keyboard or mouse. The Dresden-based researchers have integrated their system"s eye tracker and image reproduction on a CMOS chip. This makes the HMDs small, light, easy to manufacture and inexpensive.
News of the day
Clinton Says U.S. Will Work With India To Address Health Challenges, Hunger
The U.S. will work to address the health challenges facing India among other countries and will aim to improve maternal and child health care services through comprehensive dialogue, Secretary of State Hillary Clinton said on Friday after visiting a Self Employed Women"s Association (SEWA) trade outlet in Mumbai, India, PTI/Yahoo! News reports. Clinton said, "Our government is already spending a lot of money on HIV/AIDS but we wanted to add maternal and child health to that commitment as it is important for India." She added that the funding will be used to combat tuberculosis and polio, "which are also problems in India" (7/18).
Health Insurance

Alcon Commences Phase 2 Clinical Trial Of NovaBay's NVC-422 For Viral Conjunctivitis

Alcon, Inc. (NYSE: ACL) and its partner, NovaBay Pharmaceuticals, Inc. (NYSE-AMEX: NBY), announced that Alcon has begun treating patients in a Phase 2 clinical trial of NovaBay"s patented lead Aganocide® compound, NVC-422, for viral conjunctivitis, a type of "pink eye." Conjunctivitis is a pervasive and painful condition that affects both adults and children, leading to more than four million doctor and emergency room visits in the United States each year. NovaBay has a licensing and research collaboration agreement with Alcon, the world"s leading eye care company, for use of its Aganocide® compounds in the eye, ear and sinus, and in contact lens solutions. Developed by NovaBay to mimic the body"s defense against infection, Aganocides® are proprietary synthetic analogs of the same molecules used by white blood cells to destroy harmful microbes in the body, such as viruses and bacteria. Because of their natural mechanism of action, NovaBay believes that Aganocide® compounds have a low potential for generating microbial resistance, offering a potential solution to the problem of rising resistance of microbes to traditional antibiotics. The Phase 2 viral conjunctivitis study follows a recently completed Phase 1 trial in which safety and tolerability were successfully demonstrated in 120 healthy volunteers with no reported serious adverse events. "We are pleased to be entering mid-stage clinical testing for viral conjunctivitis," said Ron Najafi, Ph.D., chairman and chief executive officer of NovaBay. "This is the first step in the ophthalmic clinical development program for NVC-422, which has the immediate goal of developing the first effective product to address viral conjunctivitis for which there are limited treatment options." The Phase 2 multi-center, randomized, placebo-controlled trial is designed to determine the safety and efficacy of NVC-422 in people with viral conjunctivitis. The study calls for enrolling approximately 250 patients at more than 30 medical centers, mostly in the United States. "This study is an important step forward with the clinical program for this potentially dual-acting therapy to address the multiple causes of conjunctivitis. Dual action against viral and bacterial conjunctivitis is important because when an infection is diagnosed it is difficult, time-consuming and expensive to determine the underlying cause of the infection and treat it properly," said Dr. Sabri Markabi, M.D., Alcon"s senior vice president of research and development and chief medical officer. About Conjunctivitis Conjunctivitis, which can result from either viral or bacterial infection, is an inflammation of the thin, clear tissue that covers the white part of the eye and forms the inside lining of the eyelid. The viral disease is principally caused by adenoviruses, but also can be caused by other viruses, such as enterovirus. There is no specific treatment for adenoviral conjunctivitis, which can take up to three weeks or longer to clear on its own. Bacterial conjunctivitis is caused by a variety of bacteria and is largely treated with topically applied antibiotic eye drops. Regular innovation to develop newer antibiotics is required because over time antibiotics may encounter increasing bacterial resistance. About Aganocide® Compounds The Aganocide® compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically developed by NovaBay to mimic the body"s natural defense against infection. The Aganocide® compounds maintain the biological activities while improving the stability of naturally occurring N-chlorinated antimicrobial molecules. These highly differentiated compounds may deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of antibiotic-resistant bacterial strains. In preclinical testing, the Aganocide® compounds have been shown to be highly effective against bacteria, viruses and fungi. They also have been demonstrated to be effective against bacteria in biofilms, which render most antibiotics ineffective. Aganocides have a broad therapeutic index while providing a high degree of potency, good tolerability as well as dosing versatility and flexibility. About Alcon Alcon, Inc. is the world"s leading eye care company, with sales of approximately $6.3 billion in 2008. Alcon, which has been dedicated to the ophthalmic industry for more than 65 years, researches, develops, manufactures and markets pharmaceutical products, surgical equipment and devices, contact lens care solutions and other vision care products that treat diseases, disorders and other conditions of the eye. For more information on Alcon, Inc., visit the Company"s web site at http://www.alcon.com. NovaBay Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009